3Mdiet
3 ingestas diarias
4M
Mentation, medications, mobility, y What Matters Most
5As
Ask premisssion, Assess, Advise on management, Agree on plan, and Assist with drivers and barriers
6Mdiet
6 pequeñas ingestas
AA
Adicción Alimentaria
AA
Anti aldosterona
AACE/ACE
American Association of Clinical Endocrinologists/American College of Endocrinology
AAFP
American Academy of Family Phisician
AAI
Administración Automatizada de Insulina
AANP
American Association of Nursey Practicionaire
AAO
American Academy of Ophthalmology
AAP
American Academy of Pediatrics
AAPA
American Academy of Phisician Association
AAS
Ácido Acetil Salicílico
AASLD
American Association for the Study of Liver Diseases
ABSI
A Body Shape Index (Índice de forma corporal A)
ACC
American College of Cardiology
ACCORD
Action to Control Cardiovascular Risk in Diabetes Trial.
ACCORD-BP
Action to Control Cardiovascular Risk in Diabetes- Blood Pressure
ACCORD-EYE
Action to Control Cardiovascular Risk in Diabetes Eye
ACCORD-ION
Action to Control Cardiovascular Risk in Diabetes Follow ON
ACCORD-MID
Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes
ACE2
Angiotensin-Converting Enzyme 2 o enzima convertidora de la angiotensina 2
ACG
AutoControl de Glucemia
ACLS
Aerobics Center Longitudinal Study
ACOD
AntiCoagulante Oral Directo
ACOFP
Colegio Americano de Médicos de Familia Osteopatas
ACP
American College of Physicians
ACR
Adenoma ColoRrectal
ACR
Aptitud CardiorRespiratoria
ActRII
receptor II de la activina tipo II
ACV
Accidente CerebroVascular
ADA
American Diabetes Association
ADAPTABLE
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness
ADDITION-Cambridge
Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in PrimaryCare
ADF
Alternate Day Fasting
ADH
Alcohol DesHidrogenasa
ADI
índice de deprivación de área (Area Deprivation Index)
ADJUNCT
Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
ADNI
AntiDiabéticos No Insulínicos
ADOPT
A Diabetes Outcome Progression Trial
ADRR
Average Daily Risk Range
ADVANCE
Action in Diabetes and Vascular Disease : Preterax and Diamicron Modified Release Controlled Evaluation
ADVANCE-BP
Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation Blood Pressure
ADVANCE-ON
Action in Diabetes and Vascular Disease Study-Observational Study
ADVOR
Acetazolamide in Decompensated heart failure with Volumen OveRload
AEI
Amputaciones Extremidades Inferiores
AES
American Epilepsy Society
AFFIRM-AHF
Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure
AGA
American Gastroenterological Association
AGE
Acides Gras Essentiels
AGE
Advanced Glycation End Products
AGREE II
Appraisal of Guidelines Research and Evaluation (second version)
AHA
American Heart Association
AHEAD
Action for Health in Diabetes (Look AHEAD)
AHEI
Alternate Healthy Eating Index
aHR
Hazard ratio ajustada
AHRE
episodio auricular de frecuencia alta
AHRQ
Agencia para la Investigación y Calidad de la Atención Médica
AHS-2
Adventist Health Study-2
AI
Auricula Izquierda.
AID
Automated insulin delivery (sistemas automáticos de administración de insulina)
AIIMS
Instituto de Ciencias Médicas de All India
aINS
análogo de INSulina
Akt
serine/threonine kinase
AL
Acidosis Láctica
ALA
ácido alpha linoleico
ALL-HEART
ALLopurinol and cardiovascular outcomes in patients with ischaemic HEART disease
ALLHAT-LLT
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
ALT
ALanina aminoTransferasa
AMLP
Afecciones Múltiples a Largo Plazo
AMPA
Automedida domiciliaria de la Presión Arterial.
AMPK
Proteinquinasa
AMPLITUDE-O
First Results of the Effect of Efpeglenatide on Cardiovascular Outcomes
AMSTAR
Appraisal of Guidelines Research and Evaluation II tool, A Measurement Tool to Assess Systematic Reviews
ANDIS
All New Diabetics in Scania
ANEMC
Antagonistas No-Esteroideo del receptor MineralCorticoide
ANGII
Angiotensina II
ANGPT
Angiopoyetina
ANGPTL8
ANGioPoyeTina-Like 8
Anti GAD
Glutamic Acid Decarboxylase antibodies
ANZCTR
Australian New Zealand Clinical Trials Registry
aOR
adjusted Odds Ratio (razón de probabilidad ajustada)
AP
Atención Primaria
ApCV
Aptitud CardioVascular
APEI
Amputación Extremidad Inferior
APhA
American Pharmaceutical Association
APHOSDIAB
Atención Primaria Hospitalización en pacientes con Diabetes
Apo (a)
Apolipoproteina a
ApoB
Apolipoproteina B100
APOC3
APOlipoproteína C-III
APOE4
APOlipoproteina E4
APP
Arteriopatía Periferica
APPADL
Ability to Perform Physical Activities of Daily Living Questionnaire (capacidad para realizar actividades físicas de la vida diaria)
ARA2
Antagonistas de los Receptores de la Angiotensina II
ARG
Antagonista del Receptor de Glucagón
arGLP-1
Agonistas del receptor del péptido-1 similar al glucagón
arGLP-1np
agonistas del receptor del péptido similar al glucagón-1 no peptídicos
ARIC
Atherosclerosis Risk in Communities
ARM
Antagonistas de los receptores Minerlcorticoide
ARMMS-T2D
Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes
ARMS-D
Adherencia a recargas y medicamentos: diabetes
ARNI
inhibidores de la Neprilisina
ARRIVE
Aspirin to Reduce Risk of Initial Vascular Events
ARST
Mineralocorticoid Receptor Antagonist Tolerability Study
ARST-DN
Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy
ARST-HF
Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure
ARVO
Association for Research in Vision and Ophthalmology
ASCEND
A Study of Cardiovascular Events in Diabetes
ASCOT-LLA
Anglo-Scandinavian Cardiac Outcomes Trial
ASCVD
Atherosclerotic Cardiovascular Disease
ASHP
American Society of Health-System Pharmacists
ASPREE
Aspirin in Reducing Events in the Elderly
AST
Aspartato Aminotransferasa
ATC
Antithrombotic Trialists’ Collaboration
ATP
Adenosine TriPhosphato
ATP III
Adult Treatment Panel III
AU.S
Aseguramiento Sanitario
AUC
Área bajo la Curva (Area Under the Curve)
AUCROC
Área Under the Curve ROC
AVAD
Años de vida Ajustados por Discapacidad
AVAM
Años de Vida Ajustados por Mortalidad
AWARD 11
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
AWGS
Asian Working Group for Sarcopenia
B/F
Bacteroidetes-to-Firmicutes ratio
BA
Bebidas Azucaradas
BARI-2D
Bypass Angioplasty Revascularization Investigation 2 Diabetes
BASHIP
Bavarian Association of Statutory Health Insurance Physicians
Baz
Bebidas Azucaradas
BBs
Betabloqueantes
BCF
Bayesian Causal Forest (Bosque Causal Bayesiano)
BEC
Brecha de Edad Cerebral
BES
Binge Eating Scale
Beta
Modelo Bayesiano
BGM
Blood Glucose Monitoring
BID
bomba de insulina dirigida por algoritmo
BioLINCC
Biologic Specimen and Data Repository Information Coordinating Center
BNDF
Brain derived neurotrophyc factor
BPD
Derivación BilioPancreática
BPLTTC
Blood Pressure Lowering Treatment Trialists’ Collaboration
BPROAD
Blood Pressure Control Target in Diabetes
BRACE CORONA
Continuing Versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among patients hospitalized with coronavirus disease 2019 (COVID-19) infection
BSRAA
Bloqueo del Sistema Renina-Angiotensina-Aldosterona
C&G
Cockroft-Gault
CAC
Cociente Albumina-Creatinina
CaCo
Cancer de Colon
CAD
Cetoacidosis diabética
CAGRI
Cagrilintida
CagriSema
Cagrilintida y semaglutida
CALIBER
Cardiovascular disease research using Linked Bespoke studies and Electronic health Records
CANTAYA-SU
Canagliflozin _treatment and Trial Analysis-Sulfonylurea
CANVAS
Canagliflozin Cardiovascular Assessment Study
CAPTURE
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
CARDIA
Coronary Artery Risk Development in Young Adults
CARE
Consultation And Relational Empathy
CaReMe
CArdioRenal and Metabolic
CARMELINA
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus
CAROLINA
CARdiovascular Outcomestudy of LINAgliptin versus glimepiride in patientswithtype 2 diabetes
CASCADE
CArdiovaSCulAr Diabetes & Ethanol
CB
Cirugía Bariátrica
CC
Circunferencia de Cintura
CCAA
Comunidades Autonomas
CCI
Cardiac Contractility Index
CCK
ColeCistoKinina
CCL
Contaje Células Leucocitarias
CCM
Chronic Care Model
CCR
Cáncer ColoRrectal
CCS
Canadian Cardiovascular Society
CCS/CHFS
Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults”
CCTG
Canadian Cancer Trials Group (CCTG
CCW
Cloning Censorship Weighting (método de clonación-censura-ponderación)
CDA
Canadian Diabetes Association.
CDARS
Clinical Data Analysis and Reporting System
CDC
Centers for Disease Control and Prevention
CDM
Clinformatics Data Mart
CDM
Core Diabetes Model
CF
Cuello Femoral
CGM
Continuous Glucose Monitoring
CHANCES
Consortium on Healthand Ageing Network of Cohorts in Europe and the United State
CHARM
Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity
CHARM-ALTERNATIVE
Candesartan in Heart Failure. Assess of Reduction in Mortality & Morbidity.
CHARM-PRESERVED
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity
CHC
Carcinoma HepatoCelular
CHESS
COVID-19 Hospitalisation in England Surveillance System
CHIEF-HF
Canagliflozin on Health status qualIty of lifE and Functional status in Heart Failure
CHS
Cardiovascular Health Study
CI
Cardiopatia Isquémica
CINAHL
Cumulative Index to Nursing and Allied Health Literature
CK-MB
Creatinina Kinasa, isoenzima específica del miocardio.
CKD-EPI
Chronic Kidney Disease Epidemiology
CKD-REIN
Chronic Kidney Disease Renal Epidemiology and Information Network
CKD273
Chronic kidney disease 273
CL
Columna Lumbar
CLEAR OUTCOMES
Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen
CM
Cirugía Metabólica
CMD
CardioMiopatía Diabética
CMDB
Conjunto Mínimo de Datos Básicos
CMM
Cáncer de Mama Metastásico
CMS
Centers for Medicare & Medicaid Services
CMUH
China Medical University Hospital
CoefV
Coeficiente de Variación
COM-B
Modelo de Capacidad, Oportunidad, Motivación y Comportamiento
CONCOR
Cancer survival in five continents: a worldwide population-based study
CONFIDENCE
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint
CONGA
Continuous Overlapping Net Glycemic Action
CONQUER
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults
CONSORT
Consolidated Standards of Reporting Trials
CONUT
test de control del estado nutricional
Cor-SARS-2
Coronavirus–Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes Outcomes
CORDIOPREV
CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention
CORONADO
Coronavirus Disease and Diabetes Outcome
COUNTERPOINT
Contrapunto
CoV
Coronavirus
COVID19
Coronavirus Disease 2019
CP
Cancer de Pulmon
CPAP
Continuous Positive Airway Pressure
CPRD
Clinical Practice Research Datalink
CRAVED
ICD-10 symptoms of food related substance use disorder
CREDENCE
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
CRESCENDO
Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes
CRO
Cáncer Relacionado con Obesidad
CTT
Cholesterol Treatment Trialists
CUIMC/NYP
Columbia University Irving Medical Center/New York Presbyterian Hospital
CV
CardioVascular
CVD-REAL
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
CVOT
CardioVascular Outcome Trials (ensayos clínicos de seguridad cardiovascular)
DAFNE
Dose Adjustment For Normal Eating
DAPA-CKD
Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
DAPA-HF
Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
DARE-19
Dapagliflozin in Respiratory Failure in Patients With COVID-19
DARWIN-T2D
DAta for Real World evIdeNce in Type 2 Diabetes
DASH
Dietary Approaches to Stop Hypertension
DAWN
Diabetes Attitudes, Wishes and Needs
DAWN2
Diabetes Attitudes, Wishes and Needs 2 (segunda edición)
DBCD
dysglycemia-based chronic disease (disglucemia crónica)
DBHC
Dieta Baja en Hidratos de Carbono
DCCT
Diabetes Control and Complications Trial
DCMP
Diabetes Care Management Program
DDS
Escala de angustia por diabetes
DE
Desviación Estandar
DECLARE
Dapagliflozin Effect on Cardiovascular Events
DECLARE-TIMI 58
Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58
DEFINE-HF
Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction
DEG-100
Degludec 100 UI
DELIVER
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure
DEPICT-1
Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes
DES
Diabetic Eye Screening
DESIR
Epidemiological Study on the Insulin Resistance Syndrome
DET
Diferencia Estimada del Tratamiento
DEXA
Dual energy x-ray absorptiometry
DFF
Dosis Fija de Farmacos
DFNP
fibras nerviosas intraepidermicas
DG
Diabetes Gestacional
DHC
Dieta HipoCalórica
DIACORE
Diabetes Cohorte
DIAL
Diabetes Lifetime-perspective prediction
DIDMOAD
Diabetes Insipida, Diabetes Mellitus, Atrofia Optica y Sordera (D "deafness" por su sigla en inglés)
DiRECT
Diabetes Remission Clinical Trial
DIREVA
Finnish Diabetes Register in Vasa
DISCOVER
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
DISCOVERY
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
DM
Diabetes Mellitus.
DM1
Diabetes Mellitus tipo 1
DM2
Diabetes Mellitus tipo 2
DM3
Diabetes Mellitus tipo 3
DMBHC
Dieta Muy Baja en Hidratos de Carbono
DME
Diferencia Media Estandarizada
DMHD
Diabetes Mellitus Health Database
DMO
Densidad Mineral Ósea
DMP
Diferencia Media Monderada
DMR
Dispositivo de Monitorización Remota
DPAIB
Diferencias en la PA entre los brazos
DPCRR
Danish Psychiatric Central Research Register
DPP
Diabetes Prevention Program
DPPOS
Diabetes Prevention Program Outcomes Study
DPSG
Diabetes and Pregnancy Study Groups
DREAM
Diabetes Reduction Assessment with ramipril and rosiglitazone Medication
DS
Desviación Estandar
DSM-5
Diagnostic and Statistical Manual of Mental Disorders 5
DSMES
Diabetes Self-Management, Education and Support (Educación y el Apoyo para el Autocontrol de la Diabetes)
DT
Diferencias de Tasas
DTSQ
Satisfacción con el Tratamiento de la Diabetes
DTSQc
Satisfacción con el Tratamiento de la Diabetes y cambio
DU
Departamento de Urgencias
DULA
Dulaglutida
DURATION
Efectos de exenatida una vez a la semana más dapagliflozina, exenatida una vez a la semana o dapagliflozina, añadida a la monoterapia con metformina, sobre el peso corporal, la presión arterial sistólica y los triglicéridos en pacientes con diabetes tipo 2
DXA
Absorciometría de rayos X
E PRESERVED
EMPEROR-Preserved
E REDUCED
EMPEROR-Reduced
e-BRAVE AF
smartphone Based scReEning for Atrial Fibrillation
E/I
Espiración/Inspiración
EA
Efecto Adverso
EA
Enfermedad de Alzheimer
EAET
Eventos Adversos Emergentes del Tratamiento
EAG
Efecto Adverso Grave
Eao
Estenosis Aórtica
EAS
European Atherosclerosis Society
EASA
European Aviation Safety Agency
EASD
European Association for the Study of Diabetes
EASE
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes
EASEL
Evidence for Cardiovascular Outcomes With Sodium Glucose Cotrnasporter 2 Inhibitors in the Real Word
EASL
Euopean Association for the Study of Liver
EASO
Asociación Europea para el Estudio de la Obesidad de "European Association for the Study of Obesity"
ECA
Ensayo Clinico Aleatorizado
ECANICV
Ensayos Clínicos Aleatorizados de No Inferioridad CardioVascular
ECC
Evento Coronario
ECDPs
Expert Consensus Decision Pathways (ECDPs)
ECG
Electrocardiograma.
ECM
Enfermedad CardioMetabólica
ECV
Enfermedad CardioVascular
ECVa
Enfermedad Cardiovascular Arteriosclerótica
EDICT
Epidemiology of Diabetes Interventions and Complications
EDRFA
Encuestas Dietéticas Retrospectivas de Frecuencia Alimentaria
EDWPOP
European Diabetes Working Party for Older People
EFA
Entrenamiento Físico Aeróbico
eFI
electronic Frailty Index
EGIR
European Group for the study of Insulin Resistence
EH
Estancia Hospitalaria
EHGNA
Enfermedad Hepática Grasa No Alcohólica (equivalente a NAFLD)
EHMet
Enfermedad Hepática Metabólica (equivalente a MAFLD)
EIRA
Epidemiological Investigation of Rheumatoid Arthritis
ELF
Enhanced Liver Fibrosis
ELIXA
Evaluation of LIXisenatide in Acute Coronary Syndrome
EM
Edad Media
EMA
Agencia Europea de Medicamentos
EMD
Edema Macular Diabético
EMDAC
Endocrinologic and Metabolic Drugs Advisory Committee
EMMY
Empagliflozin in acute Myocardial Infarction trial
EMPA-HEART CardioLink-6
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes Cardiolink-6
EMPA-KIDNEY
The Study of Heart and Kidney Protection With Empagliflozin
EMPA-REG OUTCOME
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose
EMPA-RESPONSE-AHF
Empaglifozin on clinical outcomes in patients with acute decompensated heart failure
EMPA-TROPISM
Safety and Efficacy of Empagliflozin versus Placebo on Top of Guideline-directed Medical Therapy in Heart Failure Patients with Reduced Ejection Fraction without Diabetes
EMPHASIS-HF
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure
EMPEROR Pooled
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure pooled
EMPEROR-Preserved
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction
EMPEROR-Reduced
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction
EMPRISE
EMPagliflozin compaRative effectIveness and SafEty
EMPULSE
EMPagliflozin initiated in patients hospitalized for acUte heart faiLurewho have been StabilisEd
EN
Emociones Negativas
END
Enfermedades NeuroDegenerativas
EP
Enfermedad de Parkinson
EPA
ácido eicosapentaenoico
EPC
Escala de Progresión Clínica
EPIA
Exceso de Peso Inducido por los Antipsicóticos
EPIC
European Prospective Investigation of Cancer
EPIDIAR
Epidemiología de la DIABETES y el Ramadán
EPO
Eritropoyetina
EQ-5D-3L
European Quality of Life-5 Dimensions -3Life
EQA
Estandar de Calidad Asistencial
ER
Ejercicio de Resistencia
ER/PgR
receptor hormonal estrogénico y/o progesteronico
ERA
Enfermedad Renal Aguda
ERBB2
encodes the human epidermal growth factor receptor 2 (receptor 2 del factor de crecimiento epidérmico humano 2)
ERC
Enfermedad Renal Crónica
ERD
Enfermedad Renal Diabética
ERFC
Emerging Risk Factor Collaboration
erMedDiet
Dieta Mediterranea energéticamente restrictiva
ERT
Enfermedad Renal Terminal
ES
Endocrine Society
ESC
European Society of Cardiology
ESCADIANE
Estudio sobre las características de los pacientes ancianos con diabetes en España
ESD
Efectos Secundarios aDversos
ESPEN
Sociedad Europea de Metabolismo y Nutrición
ESTRID
Epidemiological Study of Risk Factors for LADA and Type 2 Diabetes”
ETCV
Elastografía Transitoria Controlada por Vibración
ETDRS
Early Treatment Diabetic Retinopathy Study
ETIFIC
Ensayo de la titulación de enfermera de insuficiencia cardiaca en comparación con la de cardiólogo
EV
Estilos de Vida
EvCV
Evento CardioVascular
EWGSOP
European Working Group on Sarcopenia in Older People
EXAMINE
Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
EXSCEL
Exenatide Study of Cardiovascular Event Lowering
FA
Fibrilación auricular
FACS
Find cases, Assess, Confirm, and Severity
FADK
Food Addiction Denmark
FAERS
FDA’s Adverse Event Reporting System
FAH
Falta de AdHerencia
FANV
Fibrilación Auricular No Valvular
FDA
Food Drug Administration
FDC
Fixed-dose combination
FDPS
Finnish Diabetes Prevention Study
FE
Fracción de Eyección
FER/TOPI
fermetina/topiramato
FEVI
Fracción de Eyección del Ventrículo Izquierdo
FFQ
Food Frequency Questionnaire
FGe
Filtrado Glomerular estimado
FGm
FGe media
FHA
Fibrosis Hepatica Avanzada
FHS
Framingham Heart Study
FIB-4
Indice de fibrosis-4
FIDELIO-DKD
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
FIDELITY
Finerenone Cuts CV Risk in T2D Across CKD Spectrum
FIELD
Fenofibrate Intervention and Event Lowering in Diabetes
FIGARO-DKD
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
FIGHT
Functional Impact of GLP-1 for Heart Failure Treatment
FINE-HEART
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes
FINE-REAL
finerenona en un entorno de atención médica de rutina
FINEARTS-HF
Finerenone in Heart Failure with Mildly Reduced and Preserved Ejection Fraction Heart Failure According to Diabetes Status
FLOW
Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
FO
Fondo de Ojo
FOCUS
Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes
FORCE
Fatty Acids and Outcomes Research Consortium
FOURIER
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
FRA
Factor de Riesgo Atribuible
FRCM
Factor de Riesgo CardioMetabólico
FRCV
Factor de Riesgo CardioVascular
FSH
Hormona Estimulante del Folículo
GAD65
Ácido Glutámico Decarboxilasa 65 (Glutamic Acid Decarboxylase)
GALACTIC-HF
Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure
GB
Glucosa Basal
GBA
Glucosa Basal Alterada.
GC
GlucoCorticoides
GC
Grupo Control
GCK
GluCoKinasa
GCKD
Germany Chronic Kidney Disease
GCVRC
Global Cardiovascular Risk Consortium
GDS
German Diabetes Study
GEDAPS
Grupo de Estudio para la Diabetes en Atención Primaria de Salud.
GEG
Grande para su Edad Gestacional
GIMc
Grosor de la Intima-Media carotídea
GIN
Guidelines International Network
GIP
Glucose-dependent Insulinotropic Peptide (péptido inotrópico glucosa-dependiente)
GLA-300
Glargina 300 UI
GLI
Glinidas
GLP-1 R
Receptor del péptido-1 similar al glucagón
GLY
Gliburide
GMSS
Encuesta de satisfacción de medición de glucosa
GoDARTS
Observacional Genetics of Diabetes Audit and Research in Tayside Scotland
GPC
Guía de Práctica Clínica
GPP
Glucosa PostPrandial
GPRD
General Practice Research Database
GRADE
Grading of Recommendations Assessment, Development, and Evaluation
GRADE study
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
GTHS
Globulina Transportadora de las Hormonas Sexuales
GTZ
Glitazonas (Tiazolidinedionas)
HARMONY
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease
HARPdoc
Hypoglycaemia Awareness Restoration Programme
HbA1c
Hemoglobina glicada, glucada o Glucohemoglobina.
HBPM
Heparinas de Bajo Peso Molecular
HC
Hidratos de Carbono
HCE
Historia Clínica Electrónica
HCL
Hybridclosed-loop (sistema hibrido cerrado)
HCQ
HidroxiCloroQuina
HDL-c
lipoproteínas de alta densidad-colesterol (High Density Lipoptotein)
hdPS
high-dimensional propensity score
HER2 O HER2/NEU
factor de crecimiento epidérmico humano 2
hERG
Human Eter-a-go-go-relatd
HES
Hospital Episodes Statistics
HF
Hipercolesterolemia Familiar
HF-ACTION
Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training
HFHe
Hipercolesterolemia Familiar Heterocigota
HFSA
Heart Failure Society of American
HGI
Hemorragia GastroIntestinal
HGNA
Higado Graso No Alcohólico
HH
Hiperglucemia Hiperosmolar
HI
Hiperinsulinemia.
HIC
Hospitalización por Insuficiencia Cardiaca
HLA
Human Leukocyte Antigens (Antigeno leucocitario humano)
HNF
Hepatocyte nuclear factor (factor nuclear de hepatocitos)
HOMA2 B
Homeostasis de la célula B pancreática
HOMA2 IR
Homeostasis insulinorresistencia
HOPE
Heart Outcomes Prevention Evaluation
HOT
Hypertension Optimal Treatment
HPFS
Health Professionals Follow-up Study
HR
Hazard Ratio
HRQoL
Health-Related Quality of Life
HRS
Health and Retirement Study
hscTnT
Troponina T cardiaca ultrasensible o de alta sensibilidad
HUNT
Trøndelag Health Study
HYGIA
HYpertension Group cronotherapy trIAl
I-PRESERVED
Irbesartan in Heart Failure with Preserved Ejection Fraction Study
I/E
criterios de Inclusión/Exclusión
I2
Heterogenicidad sustancial
IA
Inteligencia Artificial
IA2
antígeno de los islotes 2
IADPSG
International Association of the Diabetes and Pregnancy Study Groups
IAGG
International Association of Gerontology and Geriatrics
IAM
Infarto Agudo de Miocardio
IBP
Inhibidor de la Bomba de Protones
IC
Insuficiencia Cardiaca
IC 95%
Intervalo de Confianza del 95%
ICA
Índice Cintura-Altura
ICA512
autoantígeno de células de los islotes 512
ICC
Insuficiencia Cardíaca Congestiva
ICCa
Indice cintura/cadera
ICD
International Classification of Diseases
ICD-10
International Classification of Diseases ten revision
ICD-9
International Classification of Diseases nine revision
ICE
Indice cintura/estatura
ICERs
índices de coste-efectividad incrementales
ICES
Institute for Clinical Evaluative Sciences
ICFELR
Insuficiencia Cardíaca con Fracción de Eyección Levemente Reducida
ICFEmr
Insuficiencia cardiaca con fracción de eyección minimamente reducida
ICFEp
IC con FE persistente
ICFEP
Insuficiencia Cardiaca con Fracción de Eyección Preservada
ICFER
Insuficiencia Cardiaca con Fracción de Eyección Reducida
ICFErec
Insuficiencia Cardiaca con Fracción de Eyección del Ventriculo Izquierdo recuperada
ICi
Intervalo de Confianza incierto
ICL
Inercia CLínica
ICS
Instituto Catalá de la Salud
ICSI
Institute for Clinical Systems Improvement
ICT
Indice CardioTorácico.
IDB
índice dedo-brazo
IDF
International Diabetes Federation.
IDM
Inyecciones Diarias Múltiples
iDPP4
Inhibidores de la dipeptidilpeptidasa 4
IECA
Inhibidores de la Enzima Conversora de la Angiotensina
IEV
Intervencion en Estilos de Vida
IG
Índice Glucémico
IGF
Factores de crecimiento
IGG
Indicador de gestion de la glucemia
IGLA
Insulina glargina
IL
Interleucina o InterleuKina
IMC
Indice de masa corporal.
IMCMD
IMC mayor antes del debut de la DM2
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin Efficacy International Trial
IMVI
índice de masa del VI
IN CONTROL
Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia
InCC
índice de depósito Cálcico Coronario
IndCC
Indice de Contractilidad Cardiaca
INRA
Inhibidores de la Neprilisina y de los Receptores de Angiotensina 2
INS
Insulina
INS DEGL
Insulina Degludec
INS Ico
Insulina Icodec
INS NPH
Insulina Neutra Protamina de Hagedorn
INSAL
Análogos de insulina prolongada
INSB
Insulina Basal
INSB Fc
Insulina basal efsitora alfa ( LY3209590)
INSG
Insulina Glargina
INSH
Insulina Humana
INSIGHT
Intervention as a Goal in Hypertension Treatment
INSR
Insulina Regular
INVICTUS
rIvaroxaban iN rheumatIC hearT disease-aSsociated atrial fibrillation
IOS
International Organization for Standardization (Organización Internacional de Normalización)
IPAQ-SF
Physical Activity Questionnaire Short Form
IPC
índice de peptido C
iPCSK9
inhibidores de la Proproteína Convertasa Subtilisina/Kexina tipo 9
IPE
etil icosapenteno
IPTW
Inverse Probability of Treatment Weighting (sistema de ponderamiento de la posibilidad tratamiento) inverso
IQR
Rango Interquartil
IRC
Insuficiencia Renal Crónica
IRD
Diabetes relacionada con la herencia
IRIS
Insulin Resistance Intervention after Stroke
IRIS
Intelligent Research in Sight
IRR
Incidence Rate Ratio (Tasa de Incidencia Ajustada)
iSGLT2
Inhibidores del cotransportador de sodio-glucosa 2
iSRAA
inhibidores del Sistema Renina-Angiotensina-Aldosterona
IT
Inercia Terapéutica
ITG
Intolerancia a la glucosa
IV
IntraVenosa
IW-SP
Impact of Weight on Self-Perceptions (Impacto del peso sobre la autopercepción)
IWGDF
International Working Group on the Diabetic Foot
JADE
Joint Asia Diabetes Evaluation
JHU
Johns Hopkins University
JUPITER
Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
K-ATP
Potasio-Adenosine TriPhosphato
K+
Potasio
kB
proteasoma de ubiquitina
KCCQ
Kansas City Cardiomyopathy Questionnaire
KCCQ-CS
Kansas City Cardiomyopathy Questionnaire Clinical summary Score
KCCQ-TSS
Kansas City Cardiomyopathy Questionnaire Total Symptom Score
KDIGO
Kidney Disease: Improving Global Outcomes
KFRE
Kidney Failure Risk Equation (Ecuación de Riesgo de Insuficiencia Renal)
KOSS
King’s Obesity Staging Score
KOSS
Knee injury and Osteoarthritis Outcome Score
KPNC
Kaiser Permanente Northern California
LABS-2
Longitudinal Assessment of Bariatric Surgery–2
LADA
Latent Auto-immune Diabetes in Adults
LAGB
técnica de una banda gástrica laparoscópica
LDL-col
Low-Density Lipoprotein (Lipoproteina de baja densidad-colesterol)
LEADER
Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular Outcome Results
LEAN
Liraglutide Safety and Efficacy in Patients with NASH
LENS
Lowering Events in Non-proliferative retinopathy in Scotland
LFC
Liver Fat Content
LGA
Large for Gestational Age
LH
Hormona Luteinizante
LIBERATES
Improving Glucose Control in Patients With Diabetes Following Myocardial Infarction: The Role of a Novel Glycaemic Monitoring
LIBRA
LIraglutide and Beta-cell RepAir
LINA
Linagliptina
LIVE
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE
LOD
Lesión en Órgano Diana
Look aHead
Look Action for Health in Diabetes
LP(a)
Lipoproteina (a)
LPIR
resistencia lipoprotéica a la insulina
LRT
Lipoproteínas Ricas en Trigliceridos
LST
Life`s Simple 7
LTC
Centros de Atención a largo plazo
MAC
Modelo de Atención Crónica
MACE
Major Adverse Cardiovascular Events (eventos adversos cardiovasculares mayores)
MADF
Modified Alternate-Day Fasting
MAGE
amplitud media de las excursiones glucémicas
MALE
Major Adverse Limb Events (Efectos adversos mayores en las extremidades)
MAPA
Monitorización Ambulatoria de la Presión Arterial.
MAPK
Mitogen-Activated Protein Kinases (proteincinasa de activación mitogénica)
MARD
Diabetes leve relacionada con la edad
MASH
Metabolic Associated SteatoHepatitis -esteatohepatitis asociada a disfunción metabólica-
MASLD
Metabolic Dysfuntion Associated Steatotic Liver Disease
MAST
MRI+AST (Magnetic Resonance Imaging+ Aspartato Aminotransferasa)
MBE
Metodología Basada en la Evidencia o Medicina Basada en la Evidencia
MCC
Muerte por Cualquier Causa
MCG
Monitorización Continua de Glucosa
MCGeint
MCG de escaneo intermitente
MCGtr
MCG en tiempo real
MCP-1
proteína quimiotáctica de monocitos tipo 1
MCV
Muerte de causa CardioVascular
MD
Mediana de Diferencia de medias
MDRD
Modification of Diet in Renal Disease
MEASURE-HF
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
MedDiet
Dieta Mediterránea
MERS
Síndrome Respiratorio de Medio Oriente
MERS-CoV
Middle East Respiratory Syndrome-related CoronaVirus
MesH
Medical Subject Headings
MET
Metformina
MET
Metabolic Equivalents Task (equivalentes metabolicos por hora)
MetALD
Metabolic dysfunction and alcoholic liver disease (enfermedad hepática metabólica y relacionada/asociada con el alcohol )
MEV
Modificación de Estilos de Vida
MFR
Multiples Factores de Riesgo
MGC
Masa grasa Corporal
MGH
Massachusetts Hospital General
MiDG
Metformina versus insulina en Diabetes Gestacional
mitoKATP
Potasio sensible al trifosfato de adenosina
MiTyDG
Metformin in Women With Type 2 Diabetes in Pregnancy
MLTC
Multiple Long-Term Conditions
MM
Masa Magra
MMSE
Mini-Mental State Examination
MNA
Mini Nutritional Assessment
MOBA
Norwegian Mother, Father and Child Cohort Study
MOD
Diabetes relacionada con la obesidad
MODY
Maturity-Onset Diabetes of the Young
MOMPOD
Metformin vs Placebo Plus Insulin for Type 2 Diabetes or Overt Diabetes Early in Pregnancy
MOOSE
Meta-analysis Of Observational Studies in Epidemiology
MRAS
Mineralocorticoid Receptor Antagonists (antagonistas de los receptores mineralocorticoides)
MRE
Magnetic Resonance Elastography
MRI
Magnetic resonance imaging (Imagen por resonancia magnética)
MSC
Ministerio de Sanidad y Consumo
mTOR
mammalian Target Of Rapamycin
MTP
Medicamento Tradicional a base de Plantas
MUFA
Mono- Unsaturated Fatty Acids
MUST
Malnutrition Universal Screening Tool
mYFAS
Modified Yale Food Addiction Scale
n
número
N Engl J Me
New England Journal of Medicine
NA
Neuropatía Autonómica
Na
Sodio
NAC
Neuropatia Autonómica Cardíaca
NAFLD
Non-Alcoholic Fatty Liver Disease (esteatosis hepática no alcohólica)
NAL/BUP
naltrexona/bupropion
NASH
Non-Alcoholic SteatoHepatitis (esteatohepatitis no alcohólica)
NASH-CRN
Nonalcoholic Steatohepatitis - Clinical Research Network
NCCMERP
National Coordinating Council for Medication Error Reporting and Prevention.
NCD RisC
NCD Risk Factor Collaboration
NCEP US
National Cholesterol Education Programme.
NCI
National Cancer Institute
NCV
Neuropatía Cardiovascular Autonómica
NDA
National Diabetes Audit
NDDG
National Diabetes Data Group
NDEP
National Diabetes Education Program
NDIT
Neuropatia Diabética Inducida por el Tratamiento
NDM
Nefropatia Diabética
NDMA
N_Nitrosodimetilamina
NDPP
National Diabetes Prevention Programme
NDTI
National Disease and Therapeutic Index
NESDA
Netherlands Study of Depression and Anxiety
NF
Nuclear Factor
NGC
National Guidelines Clearinghouse
NGSP
National Glycohemoglobin Standardization Program
NHANES
National Health and Nutrition Examination Survey
NHI
National Health Insurance
NHIA
National Health Insurance Administration
NHIRD
National Health Insurance Research Database
NHLBI
National Heart Lung and Blood Institute
NHMRC
Australian Government National Health and Medical Research Council
NHS
National Health Scottish
NHS
Nurses’ Health Study
NICE
National Institute for Clinical Excellence.
NIDDK
National Institute of Diabetes and Digestive and Kidney Diseases
NIH
National Institutes of Health
NIS
Nationwide Inpatient Sample
NLA
National Lipids Association (Asociación Nacional de Lípidos)
NLRP3
NOD-like receptor Pyrin domain containing 3
NMA
Network-Meta Analysis
NNH
Número necesario a tratar para producir un evento adverso
NNT
Número Necesario a Tratar
NNT10
Numero Necesario a Tratar en 10 años
NNTT
Nuevas Tecnologias
NPD
Neuropatía diabética
NPDP
Neuropatía diabética Periférica
NRS
National Register of Scotland (Registro Nacional de Escocia)
NT-proBNP
fracción N terminal de la prohormona del peptido natriurético cerebral
NU-AGE
New dietary strategies addressing the specific needs of elderly population for an healthy ageing in Europe
NYHA
New York Heart Association
OASIS
Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity
OBSERVE-4D
A real-world meta-analysis of 4 observational databases
OCT
Optical Coherence Tomography (tomografía de coherencia óptica)
ODYSSEY OUTCOMES
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
OECD
Organisation for Economic Co-operation and Development
OMD
Osteomielitis
OMS
Organización Mundial de la Salud
ON
Óxido Nítrico
ONCE
Organización Nacional de Ciegos de España
ONS
Office for National Statistics
ONWARDS
Hacia Delante
OPG
OsteoProteGerina
OPN
OsteoPoNtina
OR
Odds Ratio
ORLI
Orlistat
ORMD-801
Insulina oral Oramed
OVR
Oclusion de la Vena Retiniana
PA
Presión Arterial
PAD
Presión Arterial Diastólica
PANTHER
P2Y12 inhibitor monotherapy in patients versus Aspirin in patieNTs witH coronary artERy disease
PARADIGM-HF
Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
PARADISE´MI
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction
PARAGON
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction
PARALLAX
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
PAS
Presión Arterial Sistólica
PASI
Photoplethysmography-derived Arterial Stiffness Index (índice de rigidez arterial derivado de fotopletismografía)
PC
Perímetro de Cintura
PCDE
Primary Care Diabetes Eurrope
PCDS
Primary Care Diabetes Society
PCh
Pie de Charcot
PCI
Práctica Colaborativa Interprofesional
PCORnet
National Patient-Centered Clinical Research Network
PCP
Primary Care Physician
PCR
prueba de reacción en cadena de la polimerasa
PCS
ProCalcitonina Sérica
PCSK9
Proprotein Convertasa Subtilisin Kexin 9
PCV13
Polisacaridos conjugada valente 13
PCV15
Polisacaridos conjugada valente 15
PDA
Polish Diabetes Association
PDC
Proporción de Días Cubiertos
PDM
Pie Diabético
PEP
Pequeño para su Edad Gestacional
PEP-CHF
Perindopril in Elderly People with Chronic Heart Failure
PERCEDIME
Prevalencia de la Enfermedad Renal Crónica En pacientes con DIabetes MEllitus tipo 2 en las consultas de atención primaria
PET
Positron Emission Tomography (Tomografia por Emisión de Positrones)
PGA
Perfil Glucémico Ambulatorio
PGE-loxenatide
PolyEthylene Glycol loxenatide
PHQ-9
Patient Health Questionnaire-9
PICO
Population, Intervention, Control, and Outcomes”
PIMB
Países de ingresos Medios y Bajos
PIO
Pioglitazona
PIONEER
Peptide InnOvatioN for Early DiabEtes TReatment
PmedDiet
Pesco-Mediterranean diet -PmedDiet
PNA
PoliNeuropatía Autonomica
PP
Prevencion Primaria
PPRAα
Peroxisoma Proliferador-Activador del Receptor alfa
PPROMs
Patient reported outcome measures
PPSDiab
post gestational diabetes study
PPSV23
Vacuna Neumocócica de polisacáridos 23 valente
PRED
PREDiabetes
PREDAPS
PREDiabetes en Atención Primaria de Salud
PREDIM
índice de evaluación de la homeostasis y la sensibilidad a la INS
PREDIMED
PREvención con DIeta MEDiterránea
PREDIMED-PLUS
PREvención con DIeta MEDiterránea-Plus
PRESERVED-HF
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
PRIORITY
Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROactive
PROspective pioglitAzone Clinical Trial In macroVascular Events
PROMINENT
Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes
PROSPER
Pravastatin in elderly individuals at risk of vascular disease
PROSPERO
International Prospective Register of Systematic Reviews
PROVALID
Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers
PRR
tasa proporcionales por año
PS
Propensity scores (puntaje por propensión)
PTH
Paratohormona
PTPN22
proteína tirosina fosfatasa no receptora tipo 22
PUFA
Poly- Unsaturated Fatty Acids
PY
Person/Year (persona/año)
PYY
Péptido YY
QALYs
Quality Adjusted Life Year (años de vida ajustados por calidad neta)
QRISK2
QRISK cardiovascular disease risk algorithm
QUICKI
Quantitative Insulin sensitivity ChecK Index
R2
R cuadrado (rango de coeficiente de determinación)
RADIEL
Finnish Gestational Diabetes Prevention Study
RALES
Randomized Aldactone Evaluation Study
RAMQ
Régie de l’Assurance Maladie du Québec
RAP
Riesgo Atribuible Poblacional
RC
Restricción Calórica
RCE
Ratios de Coste-Efectividad
RCV
Riesgo CardioVascular
RD
reducción de riesgo
RD
Retinopatia Diabética
RDL
Retinopatia Diabética Leve
RDNP
Retinopatia Diabética No Proliferativa
RDP
Retinopatia Diabética Proliferativa
RECORD
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes
RECORD-PE
The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology
RedGDPS
Red de Estudios de la Diabetes en Atención Primaria de la Salud
REDUCE-AMI
The aim of the randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction
REDUCE-IT
Reduction of Cardiovascular Events with EPA-Intervention Trial
ReFLeCT
Results From Real-World Clinical Treatment With Tresiba
REGARDS
Reasons for Geographic and Racial Differences in Stroke
REGICOR
Registre Gironí del Cor
REHAB-HF
REhabilitation Therapy in Older Acute Heart Failure Patients
RESPECT-EPA
Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid
RETA
Retatrutide
REWIND
Researching cardiovascular Events with a Weekly INcretin in Diabetes
RI
Resistencia a la insulina
RIC
Rango InterCuartil
RIGHT
Reporting Items for Practice Guidelines in Healthcare
RISE
Restoring Insulin Secretion
RL
Reinforcement Learning
RMNC
Resonancia Magnética Nuclear Cardíaca
RNAO
Registered Nurses' Association of Ontario
RNM
Resonancia Nuclear Magnética
RNM-PDFF
Resonancia Nuclear Magnética – Proton Density Fat Fraction
ROCKET AF
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
ROSE
The Retrospective Study of Cardiovascular Events Related to the Use of Glucose-Lowering Drug Treatment in Primary Care
ROSG
Rosiglitazona
RPM
Ratio de posesión de medicamentos
RR
Risc Ratio
RRI
Respuesta Rápida de la Insulina
RRR
Reducción del Riesgo Relativo
RT-PCR
Reverse Transcriptase Polymerase Chain Reaction (reacción en cadena de la polimerasa con transcripción inversa)
rtCGM
real-time continuous glucose monitoring (monitorización continua de glucosa en tiempo real)
RWD
Real World Evidence (datos de la vida real)
RYGB
técnica de bypas en Y de Roux
S/V
Sacabutril/Valsartan
SAE
Sesiones de Apoyo y Educación
SAHOS
Síndrome de Apnea hipopnea Obstructiva del Sueño
SAID
Diabetes Autoinmunidad Severa
SARC-F
Strength, Assistance Walking, Rise from a Chair, Climb Stairs, and Falls
SAVOR-TIMI
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction
SCA
Sudden Cardiac Arrest (paro cardiaco súbito)
SCALE
Satiety and Clinical Adiposity – Liraglutide Evidence in individuals with and without diabetes
SCDC
Shanghai Municipal Center for Disease Control and Prevention
SCI-Diabetes
Scottish Care Information-Diabetes
SCORE
Systematic Coronary Risk Evaluation
SCORED
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
SCPI
Índice de habilidades, confianza y preparación
SD
Sarcopenia Diabética
SDRN-NDS
Scottish Diabetes Research Network–National Diabetes Study
SEARCH
SEARCH for Diabetes in Youth
SECURE
SEcondary prevention of Cardiovasc UlaR disease in the Elderl
SELECT
Semaglutide effects on heart disease and stroke in patients with over weigh to obesity
SELECT-CVOT
SELECT-CardioVascular OuTcome
SEMA
Semaglutide
SF-36
Short Form 36 (Encuesta breve de salud de 36 items)
SGA
Small for Gestacional Age
SIDD
Diabetes con deficiencia severa de insulina
SIDIACO-RETRO
Sitagliptin Treatment in Diabetic COVID-19 Positive Patients
SIDIAP
Spanish Information System for the Development of Research in Primary Care
SIGN
Scottish Intercollegiate Guidelines Network
SIR
Standardized Incidence Ratio (ratio de incidencia estandarizado)
SIRD
Severe Insulin Resistance (Diabetes Diabetes con resistencia grave a la Insulina)
SHBG
Sex Hormone Binding Globulin
SLD
Steatotic Liver Disease
SM
Síndrome Metabólico
SMBG
Sistema de Monitorización de Glucosa Basal
SMC
Standars of Medical Care
SMCG
Sistema de Monitorización Continua de Glucosa
SMCG-int
SMCG de escaneo intermitente
SMCG-tr
SMCG en tiempo real
SMS
Servicio de Mensajes Simples
SNP
nucleótidos de un solo polimorfismo
SNS
Sistema Nacional de Salud
SNUS
Swedish smokeless tobacco
SOG
Prueba de Sobrecarga o tolerancia oral a la glucosa.
SOLOIST-WHF
Sotagliflozin on Cardiovascular Events in Patients With Diabetes and recient Heart Failure
SOPQ
Síndrome de Ovario PoliQuistico
SOS
Swedish Obese Subjects
SOSR
Scandinavian Obesity Surgery Registry
SOTA
Sotagliflocina
SOUL
Semaglutide cardiOvascular oUtcomes triaL
SOURMOUNT
Study of Tirzepatide in Participants With Obesity or Overweight
SPD
Sistema Personalizado de Dosificación
SPLENDID
Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death
SPLENDOR
Surgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk
SPPB
Short Physical Performance Battery
SPRINT
Systolic Blood Pressure Intervention Trial
SRAS
Síndrome Respiratorio Agudo Severo
SRAS-CoV-2
Síndrome Respiratorio Agudo Severo por CoronaVirus 2
SRDA
Sindrome de Distres Respiratorio Agudo
SSDMS
Shanghai Standarized Diabetes Management System
SSE
Situación SocioEconómica
sST2
péptido factor de tumorogenicidad soluble de tipo 2
STAMPEDE
Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently
STAREE
Statins for Reducing Events in the Elderly
STENO 2
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
STEP
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
STEP 1
Semaglutide Treatment Effect in People with obesity
STEP HF-pEF
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
STITCH
Simplified Treatment Intervention to Control Hypertension
STRENGTH
Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia
STRIDE
Semaglutida y capacidad para caminar en personas con enfermedad arterial periférica sintomática y diabetes tipo 2
SUCRA
Surface Under the Cumulative Ranking Curve
STROBE
Strengthening of Reporting of Observational Studies in Epidemiology
SUGAR-DM-HF
StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus and Heart Failure
SUH
Servicio de Urgencias Hospitalario
SURDIAGENE
Suivi Rénal, DIAbète de type 2 et GENEtique
SURMOUNT
Study of Tirzepatide in participants with obesity or Overweigth
SURMOUNT-MMO
A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults With Obesity
SURMOUNT-OSA
Study of Tirzepatide in participants with obesity or Overweigth-Obstructive Sleep Apnea
SURPASS
Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
SURPASS COVT
Study of Tirzepatide Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
SURPASS MRI
SURPASS Magnetic Resonance Imaging
SURPASS-3 CGM
SURPASS-3 Continuous Glucose Monitoring
SURPASS-SWITCH-2
Cambio de agonistas del receptor del péptido similar al glucagón-1 a tirzepatida 5 mg
SUSTAIN
Semaglutide in Subjects with Type 2 Diabetes
SUSTAIN-6
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
SVA
Síndrome Valvular Aórtico
SWAN
Study of Women’s Health Across the Nation
T1D-GRS
Type 1 Diabetes Genetic Risk Score (puntaje de riesgo genómico de la DM1)
TAR
Time Above Range (Tiempo por encima del Rango)
TBC
Tuberculosis
TBR
Time Below Range (Tiempo por debajo del Rango)
TCF7L2
Transcripción 7 like-2
TCH
Texas Children’s Hospital
TDO
Terapia Directamente Observada
TECOS
Trial Evaluating Cardiovascular Outcomes with Sitagliptin
TEP
TromboEmbolismo Pulmonar
TER
Tiempo En Rango
TEV
Tromboembolismo Venoso
TFGe
Tasa de Filtrado Glomerular estimada
THEMIS
Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
THIN
The Health Improvement Network
THR-β
thyroid hormone receptor beta (receptor beta de la hormona tiroidea)
TI
Tratamiento Intensivo
TIME
Treatment In Morning versus Evening
TMF
Trasplante de Microbiota Fecal
TIPS-3
The International Polycap Study 3
TIR
Time in Range (Tiempo en Rango)
TIRZE
Tirzepatida
TMPRRSS2
Transmembrane Serine Protease 2 o Proteasa Transmembrana Serina 2
TNHI
Taiwan’s National Health Insurance
TOBOGM
Treatment of Booking Gestational diabetes Mellitus
TODAY
Treatment Options for type 2 Diabetes in Adolescents and Youth
TOHB
Terapia con Oxígeno HiperBárico
TOPCAT
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist
TOSCA IT
Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial
TPP
Tasa de Participación en la Prevalencia
TrA
Trastorno Alimentrio
TRE
Time-Restricted Eating
TRI
Test de Retirada de Insulina
TRIG
Triglicéridos
TriMASTER
3-way cross-over trial of precision medicine strategy of 2nd/3rd line therapy in type 2 diabetes
TRIUMPH
Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension
TRP
Tabla de Riesgo Poligénico
TRS
Terapia Renal Sustitutiva
TS
Tratamiento estandar
TSD
Técnologia Sanitaria Digital
TSE
Tasa de Sedimentación Eritrocitaria
TSGH
Tri-Service General Hospital
TSMR
Tiempo de supervivencia media restringida
TTE
Target Trial Emulation (Emulación por Ensayos clinicos aleatorizados)
TUG
time up and go
TVP
Trombosis Venosa Profunda
TZP
Tirzepatida
UAB
University of Alabama at Birmingham
UARD
Diabetes relacionado con ácido úrico
UCI
Unidad de Cuidados Intensivos.
UD
Úlcera diabética
UDP
Úlcera diabética en el pie
UHPLC-MS/MS
Ultra-High-Performance Liquid Chromatography-tandem Mass Spectrometry
UKB
UK Biobank
UKPDS
United Kingdom Prospective Diabetes Study Group.
UNATI
University of Navarra Alumni Trialist Initiative
USPSTF
US Preventive Services Task Force
VA
Veterans Affairs
VADT
Veterans Affairs Diabetes Trial
VascuQoL-6
Vascular Quality of Life Questionnaire-6
VD
Ventrículo derecho.
VD2d
Vitamin D and Type 2 Diabetes
VEGF
Vascular Endothelial Growth Factor o factores de inhibición del crecimiento vasculo-endotelial
VERIFY
Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes
VERTIS CV
eValuation of ERTugliflozin effIcacy and Safety CardioVascular
VFC
Variabilidad de la Frecuencia Cardiaca
VHA
Veterans Health Administration
VI
Ventrículo izquierdo.
VICTORIA
VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction
VITAL
VITamin D and OmegA-3 Trial
VIVIDD
Vildagliptin in Ventricular Dysfunction Diabetes
VLDL-col
Lipoproteina de muy baja densidad-colesterol
VMI
Ventilación Mecánica Invasiva
VMR
Variabilidad Media Real
VN
Vacuna antiNeumocócica
VNDS
Verona Newly Diagnosed Type 2 Diabetes Study
VTDR
Vision Threatening Diabetic Retinopathy (formas avanzadas que amenazan la visión)
WESDR
Wisconsin Epidemiologic Study of Diabetic Retinopathy
WHI
Women’s Health Initiative
WHO
World Health Organization
WHS
Women´s Health Study
WHS
Wound Healing Society
WOMAC
Western Ontario McMaster Osteoarthritis Index
WOSCOPS
West of Scotland Coronary Prevention Study
YFAS
Yale Food Addiction Scal
ZnT8
antigeno del trasportador de Zinc 8
Δ9-THC
Delta-9-tetrahydrocannabinol
Diccionario de Siglas Médicas
http://www.sedom.es/diccionario/
RAE
Acrónimos en ingles del Britis Council
1 comentario:
health
Publicar un comentario